Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GB5X
|
|||
| Drug Name |
Lulizumab pegol
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [1] | |
| Company |
Bristol-Myers SquibbPrinceton, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cell-specific surface glycoprotein CD28 (CD28) | Target Info | Modulator | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| Type I diabetes mellitus | ||||
| Measles | ||||
| Autoimmune thyroid disease | ||||
| Systemic lupus erythematosus | ||||
| Rheumatoid arthritis | ||||
| Allograft rejection | ||||
| Graft-versus-host disease | ||||
| Viral myocarditis | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | T cell activation | |||
| Pathway Interaction Database | TCR signaling in naï | |||
| TCR signaling in naï | ||||
| IL12 signaling mediated by STAT4 | ||||
| Reactome | PIP3 activates AKT signaling | |||
| Constitutive Signaling by Aberrant PI3K in Cancer | ||||
| CD28 co-stimulation | ||||
| CD28 dependent PI3K/Akt signaling | ||||
| CD28 dependent Vav1 pathway | ||||
| WikiPathways | TCR Signaling Pathway | |||
| Inflammatory Response Pathway | ||||
| Host Interactions of HIV factors | ||||
| PIP3 activates AKT signaling | ||||
| T-Cell Receptor and Co-stimulatory Signaling | ||||
| Allograft Rejection | ||||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.